Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
TME Pharma Logo
TME Pharma Growth Score
83
CB Rank
99962
Heat Score
48
TME Pharma develops biostable aptamers and substances based on mirror image nucleic acids.
Founded
obfuscation
PublicPost-IPO Debt Berlin, Berlin, Germany51-100 www.tmepharma.com/
Biotechnology
Health Care
Pharmaceutical
Overview

TME Pharma
Total Funding
obfuscation
Growth Score
83
Heat Score
48

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score83
2 pts
in past quarter
Heat Score 48
10 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About TME Pharma

CB Rank
99962
TME Pharma develops biostable aptamers and substances based on mirror image nucleic acids.
Founded
obfuscation
PublicPost-IPO Debt Berlin, Berlin, Germany51-100 www.tmepharma.com/
Biotechnology
Health Care
Pharmaceutical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Noxxon Pharma AG
Also Known As NOXXON Pharma
Operating Status Active
Stock Symbol  EPA:ALTME
Company Type For Profit
Founders  Sven Klussmann
About the Company

TME Pharma is a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin,

Germany.

Phone Number 49 30 72 62 47 0
Predictions & Insights

Growth Insight

See this Growth Insight
TME Pharma is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

NOX-A12 (olaptesed)
NOX-A12 is an L-RNA aptamer that inhibits the chemokine CXCL12 to disrupt tumor microenvironment defenses and enhance cancer treatment efficacy.
NOX-E36 (emapticap)
NOX-E36 is an L-RNA aptamer targeting the chemokine CCL2 to modulate inflammatory responses, with applications in diabetic nephropathy and other inflammatory diseases.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
2
obfuscation
— Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of Diede van den Ouden
Diede van den Ouden
—
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
—
Photo of Diede van den Ouden
Diede van den Ouden
—
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
—
Photo of Diede van den Ouden
Diede van den Ouden
—
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
—
Photo of Diede van den Ouden
Diede van den Ouden
—
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
—
Photo of Diede van den Ouden
Diede van den Ouden
—
Post-IPO Debt - TME Pharma Logo
Post-IPO Debt - TME Pharma
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 5 Board Members and Advisors 3 Contacts 3

Employee Profiles

Board Members and Advisors

News

News and Press

News•Apr 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

253
-92.34%
 in past month

IT Spend

$184.1KThis year, TME Pharma is projected to spend $184.1K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Getty Images Logo
Getty Images
84
Chat Tool Logo
Chat Tool
79
Insider Logo
Insider
74

Actively Used Products

2TME Pharma uses 2 technology products and services including HTML5, Apache Server, and  Google Fonts, according to G2 Stack.

Active Website Tech Count

3TME Pharma is actively using 3 technologies for its website, according to BuiltWith. These include CommonCrawl Top 5m and  YouTube.

Total IP

33The intellectual property of TME Pharma includes 28 registered patents primarily in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery. Additionally, TME Pharma has registered 5 trademarks with the most popular class being 'Chemical substances', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is TME Pharma's headquarters? TME Pharma is located in Berlin, Berlin, Germany.Who invested in TME Pharma? TME Pharma has 19 investors including Diede van den Ouden and  Maurizio PetitBon.When was the last funding round for TME Pharma? TME Pharma closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are TME Pharma's competitors? Alternatives and possible competitors to TME Pharma may include Q32 Bio, Roivant Sciences, and  ImageneBio.How much funding has TME Pharma raised to date? TME Pharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(f8e1fc8 1)
|